SEARCH BY
| Category | Company |
|---|---|
| Sector | Medical Products |
| Employees | 8 |
| Revenue | 2M USD (2020) |
H-CYTE was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Medical Products M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 2 of 2 |
| State: Indiana M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2022 M&A | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-09-08 |
Jantibody
United States Jantibody is a novel cancer immunotherapeutic agent that has demonstrated robust efficacy in controlling ovarian cancer and mesothelioma in preclinical models of these diseases. |
Buy | - |
